Ingestion by rats of rat placenta or amniotic fluid enhances opioid-mediated, or partly opioid-mediated. antinociception produced by morphine injection, vaginal or cervical stimulation. late pregnancy, and foot shock. This phenomenon is believed to be produced by a pla cental opioid-enhancing factor (POEF). Ingestion by rats of human or dolphin placenta has also been shown to enhance opioid antinoci ception, suggesting that POEF may be common to many mammalian species. We tested bovine amniotic fluid (BAF) for its capacity to enhance morphine antinociception in female Long-Evans rats, as determined by percentage change from baseline tail-flick latency in re sponse to radiant heat, and we report that 0.50 mL BAF effectively enhanced morphine antinociception but did not by itself produce an tinociception. The efficacy of POEF across species suggests that POEF may have been functionally (and structurally) conserved during evolution_ Furthermore, the availability of POEF at parturition, as well as its ability to enhance pregnancy-mediated antinociception with out disrupting maternal behavior, offers a tenable explanation for the long-debated ultimate causality of placentophagia.
Introduction
nociception at parturition (i.e., pregnancy-mediated analge sia [8] ) is the most likely, and possibly most valuable, Throughout mammalian evolution, many behavioral and consequence of placentophagia [101. Ingestion of placenta physiological characteristics presumably have been main or AF enhances the opioid, or partly opioid, antinociception tained (albeit with modification) or have independently con produced by the central action [4] of morphine sulfate (MS) verged, the result of which has been behavioral and mor injected peripherally [7, 11, 14, 16, 25] , foot shock [16] , vaginal phological parallelism among mammalian species. One or cervical stimulation [1, 6, 17, 28] , and late pregnancy [15] , characteristic that is recognized in all pregnant eutherian and does so via gastric vagal afferents [22,26J. More recent mammals is the presence of placenta as a secretory substrate evidence indicates that placenta ingestion preferentially en and as a pathway for selective physiological exchange be hances antinociception produced by activation of 5 or K opioid tween parent and offspring [20] . Of particular interest in the receptors, but inhibits antinociception produced by activation comparative study of mammalian behavior is the fact that at of J.L opioid receptors [3,5,11], Ingestion of placenta or AF parturition, females of almost all eutherian species engage does not, however, affect morphine-induced hyperthermia [I J in placentophagia-ingestion of placenta and amniotic fluid or nonopioid antinociception [13, 23] , nor does it produce anti (AF) [9] . nociception by itself [4, [12] [13] [14] 16, 17, 23, 251 . Because opioid The desire to understand the proximate and ultimate action is a prerequisite for the enhancing activity of ingested causes of placentophagia has inspired a variety of explana placenta and AF, Kristal et al. r14] have named the enhancing tions for the phenomenon. Although these hypotheses may factor POEF-placental opioid-enhancing factor. include evolutionarily sound consequences of the behavior,
The enhancement of opioid antinociception by ingestion such as satisfaction of specific hunger, maintenance of nest of POEF is well documented [10] , but that research has pre hygiene, and facilitation or induction of maternal behavior dominantly made use of rat placenta and AF to demonstrate [9, 18, 24] , they are typically too narrow or species specific enhancement in rats. Interestingly, there is evidence that in their scope. Alternatively, there is ample empirical evi POEF is present in bovine amniotic fluid (BAF) and that it dence to suggest that enhancement of opioid-mediated antienhances opioid analgesia in cows f21 j, and there is evi dence that POEF shows allopatric efficacy in its enhance ment; specifically, both bottlenose dolphin placenta and hu
human afterbirth materials are significant because they re veal POEF activity in each of four mammalian orders: Ro dentia, Artiodactyla, Cetacea, and Primates, respectively. Similarly, the demonstrations of allopatric efficacy are im portant because they support the suggestion that POEF, as well as the system that mediates it, is consistent across spe cies. In this study, we further explored POEFs allopatric opioid-enhancing quality by determining whether ingestion by rats of BAF enhances opioid antinociception. Whereas the POEF research on hottlenose dolphin placenta and hu man placenta revealed the cross-species effectiveness of carnivore and omnivore afterbirth material, respectively, testing BAF olTers the opportunity to reveal cross-species effectiveness of herbivore afterbirth material. We expected that BAF would show POEF activity, yet would do so only in rats already experiencing opioid antinociception. Such in teraction has heen reported many times in the research on POEF and is one of the defining characteristics of POEF.
Method
All procedures used in this research were approved by the Institutional Animal Care and Use Committee (IACUC) of the University at Buffalo. Ninety-six female Long-Evans rats were used, all of which were born and maintained in the Be havioral Neuroscience Research Facility of the University at Buffalo Department of Psychology. Rats were housed indi vidually under a 14: IO-h lightdark cycle (lights on at 0500 h EasLern Standard Time) in 24.5 X 18 X 18-cm wire mesh cages with food (Agway Prolab Rat/Mouse/Hamster Formula 3000, Syracuse, NY) and water available ad lib. All rats ex hibited normal estrous cyclicity prior to testing, had a mean body weight of 250 g, and were 75-100 days of age.
A tail-flick latency (TFL) test was used to determine anti nociceptive threshold to radiant heat applied to the tail 116]. Morphine sulfate (Sigma Chemical Co., St. Louis, MO) was administered through the i.p. route at 3.0 mg/mL per kilo gram in isotonic saline vehicle through a 25-gauge hypoder mic needle. Orogastric infusions of BAF were performed with a blunted, 16-gauge hypodermic needle fitted with an 11.5-cm length of PE-160 tubing (Clay Adams, Franklin Lakes, NJ). During testing, rats were restrained in opaque polyvinyl restraining/testing tubes (5 X 21 cm). Bovine amni otic fluid (a gift of Dr. Carlos Pinheiro Machado) and saline were maintained at -20°C until being warmed to 37°C for 20 min immediately prior to infusion.
Rats were habituated to the testing procedure on 5 con secutive days prior to testing by daily intubation without in fusion and by daily restraint for 1 h in restraining/testing tuhes. Prior to and during testing, rats were food-and water In rats injected with MS, 0.50 mL BAF produced a mean increase in TFL of 60. • Sal-injected 
Discussion
Our data confirm that BAF posscsses POEF activity and demonstrate that ingested bovine POEF enhances opioid mediated antinociception in Long-Evans rats. Injcction of morphine through the intraperitoneal route, coupled with in gestion of 0.50 mL saline, produced antinociception that was 25.437c above baseline, but morphine coupled with in gestion of 0.50 mL BAF cnhanced antinociception to a level that was 60.73% above baselinc (see Fig. I ). This enhance ment represents a I 38 C /C increase in morphine efficacy. Infusion of 0.50 mL BAF produced greater enhancement of morphine antinociception than did infusion of 0.25 mL BAF, hut 0.25 mL BAF was not different from 0.25 mL sa line. indicating that 0.50 mL BAF was the only effective dose tested. Rat AF, however, has previously been found to enhance morphine antinociception optimally when ingested at 0.25 mL yet it is also effective at 0.50 and 1.00 mL f12J.
The present data, therefore, suggest different uose-response characteristics for bovine and rat AF when tested in rats. Fi nally, as predicted, neither 0.50 nor 0.25 mL BAF in the ab sence of morphine treatment produceu a significant increase from TFL B (Fig. I, salinc-injecteu groups) . Both the dose dependent efficacy anu the inability of BAF to produce anti nociception independent of opioid antinociception are con sistent with previous findings [4, [12] [13] [14] 16, 17, 23, 25] .
POEF activity has previously been found in rat AF 14,6,7.12-15] and placenta [3,5,11,12,\6,17] when tested in rats and in BAF 1211 when tested in cows. These results, however. were obtained in assays in which the subjects tested and the PORF donors were conspecifics. Abbott et al. were the first to reveal the ability of POEF to enhance opi oid antinociception across species when they demonstrated that both bottlenose dolphin and human placenta, when in gested by Long-Evans rats, enhance opioid antinociception [11. The present data confirm the existence of POEF activity in BAF and demonstrate that ingested BAF can act allopat rically to enhance opioid antinociception in female Long Evans rats. Although the number of mammalian species in which POEF is potentially detectable far exceeds that tested to date, the research on POEF continues to return consistent results, and the expanding number of reports identifying POEF across species, even in the afterbirth of species that typically do not engage in placentophagia (i.e., bottlenose dolphin, human), suggest that POEF is uhiquitous among mammalian taxa.
Beyond the lahoratory and human environments, mor phine antinociception is unknown. Endogenous opioid anti nociception. however, occurs in several behavioral contexts, one of which is parturition l8j. Although recent work has re vealed that opioid application to the midbrain facilitates the onset of maternal behavior [27] , there is significant evi dence that high opioid levels disrupt maternal behavior [2, 19J. An antagonism potentially occurs, then, when a par turient female benefits from opioid antinociception (result ing from pregnancy and vaginal stimulation of delivery) but risks disruption of maternal behavior because of high opioid levels. This being the case. placentophagia at parturition provides an excellent opportunity for natural enhancement of endogenous opioid antinociception without disrupting maternal behavior II 0,25 J, and it is in this context that opi oid enhancement could easily provide both proximate and ultimate benefits to a parturient female 1101. This concept is particularly intriguing considering that AF is available and ingested prior to delivery of the first neonate and that partu rient females of even herbivorous species ingest their after birth. The research on POEE then, reinforces the notion of POEF as a ubiquitous component of mammalian afterbirth and suggests that the proposed function of POEF as a non disruptive, natural enhancer of endogenous opioid antinoci ceptio!1 at parturition may be just as ubiquitous.
